Wang, Xiaodong Yu, Bingying Cao, Birong Zhou, Ji Deng, Yongqiang Wang, Zhulin Jin, Guangyi
Published in
International journal of cancer
In recent years, inhibitors of the BET bromodomain proteins, such as BRD4 inhibitors, have demonstrated robust antitumor activity. JQ-1, a representative small molecular BRD4 inhibitor, is also effective to block PD-1/PD-L1 signaling by significantly decreasing the PD-L1 expression on tumor cells. However, toxicity of BRD4 inhibitors on lymphoid an...
Kaira, Kyoichi Kuji, Ichiei Kagamu, Hiroshi
Published in
Cancer Imaging
Anti-programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1) antibodies are administered in varied human cancer types. The expression of PD-L1 within tumor cells has been identified as a predictive marker, although assessing its expression has benefitted only patients with non-small cell lung cancer (NSCLC) or head and neck cancer. Whereas...
Ohe, Rintaro Kabasawa, Takanobu Utsunomiya, Aya Urano, Yuka Kitaoka, Takumi Suzuki, Kazushi Aung, Naing Ye Kawamura, Ichiro Tajima, Katsushi Ishiyama, Tomoharu
...
Published in
Diagnostic Pathology
BackgroundHistiocytic sarcoma (HS) is a rare neoplasm showing morphological and immunophenotypic features of mature tissue histiocytes. We report a patient with nodal HS exhibiting prominent reactive eosinophilic infiltration.Case presentationA 68-year-old man presented with intermittent left lower abdominal pain and weight loss over 3 months. A co...
Luo, Xiaoqing Peng, Shunli Ding, Sijie Zeng, Qin Wang, Rong Ma, Yueyun Chen, ShiYu Wang, Yanxia Wang, Wei
Published in
Cancer Cell International
BackgroundSerum Deprivation Protein Response (SDPR) plays an important role in formation of pulmonary alveoli. However, the functions and values of SDPR in lung cancer remain unknown. We explored prognostic value, expression pattern, and biological function of SDPR in non-small cell lung cancer (NSCLC) and KRAS-mutant lung cancers.MethodsSDPR expre...
Yi, Ming Niu, Mengke Xu, Linping Luo, Suxia Wu, Kongming
Published in
Journal of Hematology & Oncology
Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple cancer types, the PD-1/PD-L1 axis is the major speed-limiting step of the anti-cancer immune response. In this context, blocking PD-1/PD-L1 could restore T cells from exhausted status and ...
Sanchez, Katherine Kim, Isaac Chun, Brie Pucilowska, Joanna Redmond, William L. Urba, Walter J. Martel, Maritza Wu, Yaping Campbell, Mary Sun, Zhaoyu
...
Published in
Breast Cancer Research
BackgroundThe H&E stromal tumor-infiltrating lymphocyte (sTIL) score and programmed death ligand 1 (PD-L1) SP142 immunohistochemistry assay are prognostic and predictive in early-stage breast cancer, but are operator-dependent and may have insufficient precision to characterize dynamic changes in sTILs/PD-L1 in the context of clinical research. We ...
Costa, Federica Marchica, Valentina Storti, Paola Malavasi, Fabio Giuliani, Nicola
Published in
Cancers
The emerging role of the PD-1/PD-L1 axis in MM immune-microenvironment has been highlighted by several studies. However, discordant data have been reported on PD-1/PD-L1 distribution within the bone marrow (BM) microenvironment of patients with monoclonal gammopathies. In addition, the efficacy of PD-1/PD-L1 blockade as a therapeutic strategy to re...
Fang, Wenli Zhou, Ting Shi, He Yao, Mengli Zhang, Dian Qian, Husun Zeng, Qian Wang, Yange Jin, Fangfang Chai, Chengsen
...
Published in
Journal of Experimental & Clinical Cancer Research
BackgroundProgranulin (PGRN), as a multifunctional growth factor, is overexpressed in multiple tumors, but the role of PGRN on tumor immunity is still unclear. Here, we studied the effect of PGRN on breast cancer tumor immunity and its possible molecular mechanism.MethodsThe changes of macrophage phenotypes after PGRN treatment were detected by wes...
Vicier, Cecile Ravi, Praful Kwak, Lucia Werner, Lillian Huang, Ying Evan, Carolyn Loda, Massimo Hamid, Anis A Sweeney, Christopher J
Published in
The Prostate
Characterization of markers of both immune suppression and activation may provide more prognostic information than assessment of single markers in localized prostate cancer. We therefore sought to determine the association between CD8 and PD-L1 expression in localized prostate tumors and biochemical recurrence (BCR) and metastasis-free survival (MF...
Tambaro, Rosa Napoli, Marilena Di Pisano, Carmela Cecere, Sabrina Chiara Attademo, Laura Rossetti, Sabrina Feroce, Florinda Setola, Sergio Califano, Daniela Russo, Daniela
...
Published in
Immunotherapy
Monoclonal antibodies targeting the checkpoint inhibitors (CPIs), programmed cell death protein-1 or programmed cell death ligand-1, are changing the landscape of urothelial carcinoma therapeutics. Overall, clinical studies in metastatic or advanced urothelial cancer showed that CPIs provided a slight improvement in survival and a relevant advantag...
